Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UK reporting radiographers' perceptions of AI in radiographic image interpretation - Current perspectives and future developments.

Radiography (London, England : 1995)·2022
Same author

Racial disparities in pre-operative pain, function and disease activity for patients with rheumatoid arthritis undergoing Total knee or Total hip Arthroplasty: a New York based study.

BMC rheumatology·2020
Same author

Comparative efficacy of epidural clonidine versus epidural fentanyl for treating breakthrough pain during labor: a randomized double-blind clinical trial.

International journal of obstetric anesthesia·2019
Same author

A strategy for monitoring and evaluating massive open online courses.

Evaluation and program planning·2016
Same author

Nanocoating for biomolecule delivery using layer-by-layer self-assembly.

Journal of materials chemistry. B·2016
Same author

Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials.

Bone marrow transplantation·2013
Same journal

The expanded cardiovascular risk prediction score as a cardiovascular mortality predictor in rheumatoid arthritis.

Clinical and experimental rheumatology·2026
Same journal

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Clinical and experimental rheumatology·2026
Same journal

Clinical features and gastrointestinal bleeding risk factors in IgA vasculitis patients: a retrospective study in a large volume centre.

Clinical and experimental rheumatology·2026
Same journal

Reply to the comment on: The microbiota in axial spondyloarthritis: what have we learned from Mendelian randomisation studies?

Clinical and experimental rheumatology·2026
Same journal

Comprehensive evaluation of bone structural and microarchitectural changes in rheumatoid arthritis treated with baricitinib using HR-pQCT, imaging, and biomarker analyses.

Clinical and experimental rheumatology·2026
Same journal

Tracking interstitial lung disease in systemic sclerosis: integrating lung magnetic resonance imaging into a clinically oriented multimodal follow-up strategy.

Clinical and experimental rheumatology·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Extraction of Cofactor F420 for Analysis of Polyglutamate Tail Length from Methanogenic Pure Cultures and Environmental Samples
04:32

Extraction of Cofactor F420 for Analysis of Polyglutamate Tail Length from Methanogenic Pure Cultures and Environmental Samples

Published on: October 14, 2021

Measuring methotrexate polyglutamates.

S Goodman1

  • 1Hospital for Special Surgery, New York, NY 10024, USA. goodmans@hss.edu

Clinical and Experimental Rheumatology
|November 4, 2010
PubMed
Summary
This summary is machine-generated.

Measuring methotrexate polyglutamates may not significantly improve rheumatoid arthritis treatment efficacy or reduce adverse effects. Overlapping levels in responders and non-responders limit the clinical utility of this test.

More Related Videos

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

Related Experiment Videos

Last Updated: Jun 7, 2026

Extraction of Cofactor F420 for Analysis of Polyglutamate Tail Length from Methanogenic Pure Cultures and Environmental Samples
04:32

Extraction of Cofactor F420 for Analysis of Polyglutamate Tail Length from Methanogenic Pure Cultures and Environmental Samples

Published on: October 14, 2021

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
09:04

Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods

Published on: September 10, 2018

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Chemistry

Background:

  • Methotrexate is a primary treatment for rheumatoid arthritis.
  • 30-40% of patients show an inadequate response to methotrexate.
  • Methotrexate polyglutamates are the active metabolites of methotrexate.

Purpose of the Study:

  • To evaluate the clinical utility of measuring methotrexate polyglutamates.
  • To determine if this measurement can improve methotrexate efficacy.
  • To assess if this measurement can decrease adverse reactions.

Main Methods:

  • Review of existing literature on methotrexate polyglutamate measurement.
  • Pharmacological analysis of the relationship between metabolite levels and clinical outcomes.
  • Comparison of metabolite levels in patient groups with varying treatment responses.

Main Results:

  • Higher methotrexate polyglutamate levels correlate with improved methotrexate response.
  • No absolute correlation exists between metabolite levels and treatment effect.
  • Significant overlap in metabolite levels between responders and non-responders was observed.

Conclusions:

  • The clinical utility of measuring methotrexate polyglutamates is limited.
  • Current data do not support routine use for optimizing rheumatoid arthritis treatment.
  • Further research may be needed to refine the application of this biomarker.